Login / Signup

Are You a TMBeliever? Mutations and Atezolizumab Response in Solid Tumors.

Steven B MaronSamuel J Klempner
Published in: Cancer discovery (2022)
Optimizing the utility of tumor mutational burden in solid tumors remains an unmet need and a clinical knowledge gap. Using a centrally determined cutoff of ≥16 mut/Mb, Friedman and colleagues demonstrate an ability to enrich for atezolizumab response in a pretreated pan-cancer multibasket study. See related article by Friedman et al., p. 654 (4).
Keyphrases
  • papillary thyroid
  • squamous cell carcinoma
  • childhood cancer